• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于肿瘤特异性蛋白水解增强放射治疗的辐射响应型 PROTAC 纳米颗粒。

Radiation responsive PROTAC nanoparticles for tumor-specific proteolysis enhanced radiotherapy.

机构信息

State Key Laboratory of Natural Medicines, Key Laboratory of Drug Quality Control and Pharmacovigilance, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.

State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.

出版信息

J Mater Chem B. 2024 Mar 27;12(13):3240-3248. doi: 10.1039/d3tb03046f.

DOI:10.1039/d3tb03046f
PMID:38437473
Abstract

Proteolysis targeting chimeras (PROTACs) is a promising strategy for cancer therapy. However, the always-on bioactivity of PROTACs may lead to non-target toxicity, which restricts their antitumor performance. Here, we developed an X-ray radiation responsive PROTAC nanomicelle (RCNprotac) by covalently conjugating a reported small molecule PROTAC (MZ1) to hydrophilic PEG a diselenide bond-containing carbon chain, which then self-assembled into a 141.80 ± 5.66 nm nanomicelle. The RCNprotac displayed no bioactivity during circulation due to the occupation of the hydroxyl group on the E3 ubiquitin ligand component and could effectively accumulate at the tumor site owing to the enhanced permeability and retention effect. Upon exposure to X-ray radiation, the radiation-sensitive diselenide bonds were broken to specifically release MZ1 for tumor BRD4 protein degradation. Furthermore, the reduction in the BRD4 protein level could increase the tumor's sensitivity to radiation. RCNprotac showed a synergistic enhancement of antitumor effects both and . We believe that this X-ray-responsive PROTAC nanomicelle could provide a new strategy for the X-ray-activated spatiotemporally controlled protein degradation and for the BRD4 proteolysis enhanced tumor radiosensitivity.

摘要

蛋白水解靶向嵌合体(PROTAC)是癌症治疗的一种很有前途的策略。然而,PROTAC 的始终保持的生物活性可能导致非靶向毒性,从而限制了它们的抗肿瘤性能。在这里,我们通过将报道的小分子 PROTAC(MZ1)共价连接到亲水性 PEG 二硒键含碳链上,开发了一种 X 射线辐射响应的 PROTAC 纳米胶束(RCNprotac),然后自组装成 141.80 ± 5.66nm 的纳米胶束。由于 E3 泛素连接酶配体成分上的羟基被占据,RCNprotac 在循环过程中没有生物活性,并且由于增强的渗透性和保留效应,能够有效地聚集在肿瘤部位。在 X 射线辐射下,辐射敏感的二硒键被破坏,以特异性释放 MZ1 用于肿瘤 BRD4 蛋白降解。此外,BRD4 蛋白水平的降低可以增加肿瘤对辐射的敏感性。RCNprotac 表现出协同增强的抗肿瘤作用。我们相信,这种 X 射线响应的 PROTAC 纳米胶束可为 X 射线激活的时空可控蛋白降解以及 BRD4 蛋白水解增强肿瘤放射敏感性提供一种新策略。

相似文献

1
Radiation responsive PROTAC nanoparticles for tumor-specific proteolysis enhanced radiotherapy.用于肿瘤特异性蛋白水解增强放射治疗的辐射响应型 PROTAC 纳米颗粒。
J Mater Chem B. 2024 Mar 27;12(13):3240-3248. doi: 10.1039/d3tb03046f.
2
Tumor-targeted PROTAC prodrug nanoplatform enables precise protein degradation and combination cancer therapy.肿瘤靶向 PROTAC 前药纳米平台实现精确蛋白降解和联合癌症治疗。
Acta Pharmacol Sin. 2024 Aug;45(8):1740-1751. doi: 10.1038/s41401-024-01266-z. Epub 2024 Apr 12.
3
Hypoxia-sensitive macrocycle inclusion complexes for targeted protein degradation.用于靶向蛋白质降解的缺氧敏感大环包合物
J Control Release. 2025 Aug 10;384:113921. doi: 10.1016/j.jconrel.2025.113921. Epub 2025 May 30.
4
Hijacking the MDM2 E3 Ligase with novel BRD4-Targeting PROTACs in Pancreatic Cancer Cells.在胰腺癌细胞中利用新型靶向BRD4的PROTAC劫持MDM2 E3连接酶
Chembiochem. 2025 May 2:e202500133. doi: 10.1002/cbic.202500133.
5
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.两种现代生存预测工具 SORG-MLA 和 METSSS 在接受手术联合放疗和单纯放疗治疗有症状长骨转移患者中的比较。
Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23.
6
Discovery of a potent BRD4 PROTAC and evaluation of its bioactivity in breast cancer cell lines.一种强效BRD4蛋白降解靶向嵌合体的发现及其在乳腺癌细胞系中的生物活性评估。
Biochem Pharmacol. 2025 Nov;241:117159. doi: 10.1016/j.bcp.2025.117159. Epub 2025 Jul 12.
7
PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degraders for Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.用于治疗雌激素受体阳性晚期乳腺癌的蛋白酶靶向嵌合体(PROTAC)雌激素受体降解剂
Target Oncol. 2025 May;20(3):431-444. doi: 10.1007/s11523-025-01137-5. Epub 2025 May 6.
8
Epigenetic therapy meets targeted protein degradation: HDAC-PROTACs in cancer treatment.表观遗传疗法与靶向蛋白质降解相结合:癌症治疗中的组蛋白去乙酰化酶-蛋白酶体靶向嵌合体
Future Med Chem. 2025 Jul 16:1-13. doi: 10.1080/17568919.2025.2533113.
9
Unveiling New Triazoloquinoxaline-Based PROTACs Designed for the Selective Degradation of the ncBAF Chromatin Remodeling Subunit BRD9.揭示基于三唑并喹喔啉的新型PROTAC,其设计用于选择性降解ncBAF染色质重塑亚基BRD9。
Chemistry. 2025 Jun 17;31(34):e202404218. doi: 10.1002/chem.202404218. Epub 2025 May 20.
10
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.

引用本文的文献

1
Recent Advances in Nanomedicine: Cutting-Edge Research on Nano-PROTAC Delivery Systems for Cancer Therapy.纳米医学的最新进展:用于癌症治疗的纳米PROTAC递送系统的前沿研究
Pharmaceutics. 2025 Aug 10;17(8):1037. doi: 10.3390/pharmaceutics17081037.
2
PROTAC Delivery Strategies for Overcoming Physicochemical Properties and Physiological Barriers in Targeted Protein Degradation.用于克服靶向蛋白质降解中物理化学性质和生理屏障的PROTAC递送策略
Pharmaceutics. 2025 Apr 9;17(4):501. doi: 10.3390/pharmaceutics17040501.
3
Recent advances in the bench-to-bedside translation of cancer nanomedicines.
癌症纳米药物从实验室到临床应用转化的最新进展。
Acta Pharm Sin B. 2025 Jan;15(1):97-122. doi: 10.1016/j.apsb.2024.12.007. Epub 2024 Dec 14.
4
Precision oncology revolution: CRISPR-Cas9 and PROTAC technologies unleashed.精准肿瘤学革命:CRISPR-Cas9和PROTAC技术的释放
Front Genet. 2024 Jul 31;15:1434002. doi: 10.3389/fgene.2024.1434002. eCollection 2024.